Mitchell Goldman

9.4k citations

97 papers · 5.7k indexed · 3 hit papers · h-index 29

Impact in

Physiology top 0.2%
- Asthma and respiratory diseases
Immunology and Allergy top 0.5%
- Allergic Rhinitis and Sensitization

Papers in ⓘ

Physiology 47
- Asthma and respiratory diseases 41
Pulmonary and Respiratory Medicine 46
- Respiratory and Cough-Related Research 23
- Inhalation and Respiratory Drug Delivery 21
- Chronic Obstructive Pulmonary Disease (COPD) Research 16

Co-authors: Peter Barker (9 shared papers)Stephanie Sproule (5 shared papers)Eugene R. Bleecker (11 shared papers)J. Mark FitzGerald (8 shared papers)Magnus Aurivillius (5 shared papers)Geoffrey Gilmartin (3 shared papers)Viktoría Werkström (3 shared papers)Parameswaran Nair (3 shared papers)
Journals: Journal of Allergy and Clinical Immunology (7 papers)CHEST Journal (6 papers)Annals of Allergy Asthma & Immunology (4 papers)American Heart Journal (4 papers)Clinical Infectious Diseases (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Mitchell Goldman

96 papers receiving 5.5k citations

Hit Papers

align trajectories log scale

Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma 2017 · 716 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2016 The Lancet
2016 The Lancet

Peers

Countries citing papers authored by Mitchell Goldman

Since Specialization

Citations

This map shows the geographic impact of Mitchell Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Goldman more than expected).

Fields of papers citing papers by Mitchell Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Goldman. The network helps show where Mitchell Goldman may publish in the future.

Co-authors

The 25 scholars most cited alongside Mitchell Goldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mitchell Goldman Line = papers co-authored together Mitchell Goldman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 97 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial The Lancet ·J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T. Ferguson, William W. Busse, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Viktoría Werkström, Magnus Aurivillius, Mitchell Goldman Hit paper breakdown →	2016	984
2	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial The Lancet ·Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F. Weinstein, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Magnus Aurivillius, Viktoría Werkström, Mitchell Goldman Hit paper breakdown →	2016	976
3	Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma New England Journal of Medicine ·Parameswaran Nair, Sally E. Wenzel, Klaus F. Rabe, Arnaud Bourdin, Njira Lugogo, Piotr Kuna, Peter Barker, Stephanie Sproule, Sandhia Ponnarambil, Mitchell Goldman Hit paper breakdown →	2017	716
4	Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial Annals of Internal Medicine ·Drew J. Winston, Richard T. Maziarz, Pranatharthi Chandrasekar, Hillard M. Lazarus, Mitchell Goldman, Jeffrey L. Blumer, G Leitz, Mary Territo	2003	273
5	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies The Lancet Respiratory Medicine ·J. Mark FitzGerald, Eugene R. Bleecker, Andrew Menzies‐Gow, James Zangrilli, Ian Hirsch, Paul Metcalfe, Paul Newbold, Mitchell Goldman	2017	225
6	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma European Respiratory Journal ·Eugene R. Bleecker, Michael E. Wechsler, J. Mark FitzGerald, Andrew Menzies‐Gow, Yanping Wu, Ian Hirsch, Mitchell Goldman, Paul Newbold, James Zangrilli	2018	172
7	Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease Drugs ·Donald P. Tashkin, Stephen I. Rennard, Paula Martin, Sulabha Ramachandran, Ubaldo J. Martin, Philip E. Silkoff, Mitchell Goldman	2008	169
8	Efficacy and Tolerability of Budesonide/Formoterol in One Hydrofluoroalkane Pressurized Metered-Dose Inhaler in Patients with Chronic Obstructive Pulmonary Disease Drugs ·Stephen I. Rennard, Donald P. Tashkin, Jennifer McElhattan, Mitchell Goldman, Sulabha Ramachandran, Ubaldo J. Martin, Philip E. Silkoff	2009	165
9	Effect of budesonide/formoterol pMDI on COPD exacerbations: A double-blind, randomized study Respiratory Medicine ·Amir Sharafkhaneh, John G. Southard, Mitchell Goldman, Tom Uryniak, Ubaldo J. Martin	2011	120
10	Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma Annals of Allergy Asthma & Immunology ·Trung N. Tran, Robert S. Zeiger, Stephen P. Peters, Gene Colice, Paul Newbold, Mitchell Goldman, Bradley E. Chipps	2015	108
11	Itraconazole Prophylaxis for Fungal Infections in Patients with Advanced Human Immunodeficiency Virus Infection: Randomized, Placebo‐Controlled, Double‐Blind Study Clinical Infectious Diseases ·David S. McKinsey, L. Joseph Wheat, Gretchen A. Cloud, Mark A. Pierce, John R. Black, David M. Bamberger, Mitchell Goldman, Carolynn J. Thomas, Heidi M. Gutsch, Bruce L. Moskovitz, William E. Dismukes, Carol A. Kauffman, (unknown)	1999	106
12	Salvage treatment of histoplasmosis with posaconazole Journal of Infection ·Ángela Restrepo, Ángela María Tobón, Benjamin Clark, Donald R. Graham, Gavin Corcoran, Robert W. Bradsher, Mitchell Goldman, George A. Pankey, Thomas Moore, Ricardo Negroni, John R. Graybill	2006	95
13	Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma Annals of Allergy Asthma & Immunology ·Bradley E. Chipps, Paul Newbold, Ian Hirsch, Frank Trudo, Mitchell Goldman	2018	87
14	Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials Respiratory Research ·Nancy Kline Leidy, Lindsey Murray, Brigitta U. Monz, Linda Nelsen, Mitchell Goldman, Paul Jones, Elizabeth J. Dansie, Sanjay Sethi	2014	84
15	Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma Journal of Allergy and Clinical Immunology ·Stanley J. Szefler, James Baker, Tom Uryniak, Mitchell Goldman, Philip E. Silkoff	2007	84
16	Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation ·David M. Mannino, Ruth Tal‐Singer, David A. Lomas, Jørgen Vestbo, R. Graham Barr, Kay Tetzlaff, M Lowings, Stephen I. Rennard, Jeffrey A. Snyder, Mitchell Goldman, Ubaldo J. Martin, Deborah Merrill, Amber Martin, Jason C. Simeone, Kyle Fahrbach, Brian R. Murphy, Nancy Kline Leidy, Bruce E. Miller	2014	76
17	The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies Current Medical Research and Opinion ·Mitchell Goldman, Ian Hirsch, James Zangrilli, Paul Newbold, Xiao Xu	2017	76
18	Candida krusei Fungemia Medicine ·Mitchell Goldman, John C. Pottage, Denise C. Weaver	1993	65
19	Clearance of Fungal Burden during Treatment of Disseminated Histoplasmosis with Liposomal Amphotericin B versus Itraconazole Antimicrobial Agents and Chemotherapy ·L. Joseph Wheat, Gretchen A. Cloud, Philip C. Johnson, Patricia Connolly, Mitchell Goldman, Ann Le Monte, Deanna Fuller, Thomas E. Davis, Richard Hafner	2001	63
20	Nuclear magnetic resonance imaging in evaluation and follow-up of children treated for coarctation of the aorta Journal of the American College of Cardiology ·Robert A. Boxer, Michael A. LaCorte, Sharanjeet Singh, Rubin Cooper, Marcia C. Fishman, Mitchell Goldman, Harry L. Stein	1986	58

About Mitchell Goldman

Mitchell Goldman is a scholar working on Physiology, Pulmonary and Respiratory Medicine, Virology, Infectious Diseases and Epidemiology, having authored 97 papers that have together received 5.7k indexed citations. Recurring topics across this work include Asthma and respiratory diseases (41 papers), Respiratory and Cough-Related Research (23 papers), Inhalation and Respiratory Drug Delivery (21 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (16 papers), Antifungal resistance and susceptibility (7 papers), Fungal Infections and Studies (7 papers), Cardiac Valve Diseases and Treatments (7 papers) and Congenital Heart Disease Studies (6 papers). The work is most often cited by research in Physiology (4.0k citations), Immunology and Allergy (847 citations), Pulmonary and Respiratory Medicine (3.4k citations), Emergency Medical Services (361 citations) and Infectious Diseases (750 citations). Mitchell Goldman has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Peter Barker, Stephanie Sproule, Eugene R. Bleecker, J. Mark FitzGerald, Magnus Aurivillius, Geoffrey Gilmartin, Viktoría Werkström, Parameswaran Nair, Paul Newbold and Steven F. Weinstein. Their work appears in journals such as Journal of Allergy and Clinical Immunology, CHEST Journal, Annals of Allergy Asthma & Immunology, American Heart Journal and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact